THE TIGIT/CD226/CD155 AXIS AND THE EFFECTS OF COMBINING PD-1/PD-L1 BLOCKADE WITH TIGIT-TARGETING ANTIBODY THERAPY IN SYNGENEIC MURINE GLIOBLASTOMA MODELS

被引：1

作者：

Gokhale, Prafulla ^{[1
]}

Iorgulescu, Bryan ^{[1
]}

Klapholz, Max ^{[2
]}

Poitras, Michael ^{[1
]}

Eschle, Benjamin ^{[1
]}

Freeman, Gordon ^{[1
]}

Anderson, Ana ^{[3
]}

Reardon, David ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Penn, Philadelphia, PA 19104 USA

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

256

引用

页码：A277 / A278

页数：2

共 50 条

[21] Non-invasive imaging of the PD-1/PD-L1 pathway in syngeneic murine tumor models
Heskamp, Sandra
Molkenboer-Kuenen, Janneke D. M.
Aarntzen, Erik H.
Boerman, Otto C.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
[22] SPECT/CTimaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models
Heskamp, S.
Molkenboer-Kuenen, J. D. M.
van de Vondervoort, R. H. A. M.
Boerman, O. C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S147 - S147
[23] Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
Verkleij, Christie P. M.
Jhatakia, Amy
Broekmans, Marloes E. C.
Frerichs, Kristine A.
Zweegman, Sonja
Mutis, Tuna
Bezman, Natalie A.
van de Donk, Niels W. C. J.
CANCERS, 2020, 12 (12) : 1 - 20
[24] CD57+CD8+T cells and response to PD-1/PD-L1 blockade in patients with NSCLC
Zhou, Jianya
Sun, Wenjia
Zeng, Xun
Zheng, Jing
Qu, Jingjing
Jiang, Nan
Zhou, Jianying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
Li, Howard Y.
McSharry, Maria
Bullock, Bonnie
Nguyen, Teresa T.
Kwak, Jeff
Poczobutt, Joanna M.
Sippel, Trisha R.
Heasley, Lynn E.
Weiser-Evans, Mary C.
Clambey, Eric T.
Nemenoff, Raphael A.
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (09) : 767 - 777
[26] Anti-TIGIT antibody tiragolumab improves PD-L1 blockade via myeloid and Treg cells
Guan, Xiangnan
Hu, Ruozhen
Choi, Yoonha
Srivats, Shyam
Nabet, Barzin
Silva, John
Mcginnis, Lisa
Hendricks, Robert
Nutsch, Katherine
Banta, Karl
Duong, Ellen
Dunkle, Alexis
Chang, Patrick
Han, Joy
Mittman, Stephanie
Molden, Nandini
Daggumati, Pallavi
JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
[27] Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
Wang, Rui-Bin
Li, Yu-Chen
Zhou, Quan
Lv, Shu-Zhen
Yuan, Ke-Yu
Wu, Jiang-Ping
Zhao, Yan-Jie
Song, Qing-Kun
Zhu, Bin
WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (23) : 5935 - 5943
[28] Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
Rui-Bin Wang
Yu-Chen Li
Quan Zhou
Shu-Zhen Lv
Ke-Yu Yuan
Jiang-Ping Wu
Yan-Jie Zhao
Qing-Kun Song
Bin Zhu
World Journal of Clinical Cases, 2020, (23) : 5935 - 5943
[29] Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
Oh, Wonkyung
Kim, Alyssa Min Jung
Dhawan, Deepika
Knapp, Deborah W.
Lim, Seung-Oe
MOLECULAR THERAPY, 2025, 33 (02)
[30] Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Zuazo, M.
Arasanz, H.
Garcia Granda, M. J.
Bocanegra, A. I.
Fernandez-Hinojal, G.
Gato-Canas, M.
Martinez Aguillo, M.
Hernandez Marin, B.
Teijeira, L.
Morilla Ruiz, I.
Vera, R.
Kochan, G.
Escors, D.
ANNALS OF ONCOLOGY, 2019, 30 : 504 - 504

← 1 2 3 4 5 →